Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• All Participants

• Is in good general health.

• Agrees to use double-barrier method of birth control for at least 90 days after the last dose of study drugs.

• HCV Participants

• Has documented GT1, GT2, or GT3 chronic HCV infection.

Exclusion Criteria:

• All Participants

• Is pregnant or breastfeeding.

HCV Participants

• Has received prior HCV treatment.

• Is co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).